Wilentz Shareholder and Cannabis Law Co-Chair Michael F. Schaff coauthored an article with Wilentz attorney Lisa Gora, also a member of the Cannabis Law team, on the expansion of New Jersey’s medicinal marijuana program. In this article, they consider the impacts of Senate bill S-10, also referred to as the Jake Honig Compassionate Use Medical Marijuana Act, on New Jersey health care businesses and caregivers in connection with their access to medical cannabis.
This article was originally published in the June 2019 issue of New Jersey Law Journal Cannabis Law special section, and is reprinted here with permission.
New Jersey Law Journal
*Cannabis Law Disclaimer: Per federal law, under the Controlled Substances Act, marijuana is categorized as a Schedule I controlled substance. Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy, regardless of any state law that may authorize certain marijuana activity. Compliance with state marijuana law does not equal compliance with federal law. Legal advice provided by Wilentz, Goldman & Spitzer, P.A. is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Wilentz, Goldman & Spitzer, P.A. will not provide guidance or assistance in circumventing or violating Federal or state cannabis law or policy, and any advice provided by Wilentz, Goldman & Spitzer, P.A. should not be construed as such.